Ask AI
ProCE Banner Activity

NeoADAURA: Neoadjuvant Osimertinib ± CT vs CT Alone in Resectable EGFRm NSCLC

Conference Coverage
Slideset

In the phase III NeoADAURA study, preoperative treatment with osimertinib ± CT vs CT + placebo resulted in a statistically significant improvement in the MPR rates vs CT alone in patients with resectable stage II-IIIB EGFRm NSCLC, with more patients being down-staged prior to surgery and fewer patients being precluded from definitive surgery.

Released: June 06, 2025

Expiration: December 05, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo, Inc, Genentech, a member of the Roche Group, and PharmaMar.

AstraZeneca

Boehringer Ingelheim Pharmaceuticals, Inc.

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group

PharmaMar